Health Secretary Wes Streeting is confronting escalating demands to terminate a controversial puberty blocker clinical trial following Northern Ireland's decision to withdraw participation. The devolved administration has suspended its involvement in the UK-wide Pathways trial pending the outcome of a judicial review initiated by gender-critical campaigners.
Legal Challenge Halts Participation
Stormont's health minister, Mike Nesbitt, announced over the weekend that Northern Ireland would pause its agreement to participate until the legal process concludes. The judicial review questions the trial's safety protocols, transparency measures, and adherence to ethical principles. Nesbitt emphasized that any future decision to lift the suspension would require consultation with executive colleagues should the trial ultimately proceed.
Trial Details and Delays
The £10.7 million research initiative aims to enroll approximately 220 children under the age of 16 who are undergoing puberty. Participants will be randomly assigned to two groups: one receiving puberty blocker drugs immediately and the other after a 12-month delay. The study will monitor the physical and emotional well-being of participants over up to two years.
Recruitment for the trial has already been postponed until early April. Campaigners behind the High Court challenge are seeking an emergency injunction to prevent the trial from commencing until the case is fully resolved. Legal correspondence has been dispatched to the medical regulators overseeing the trial, with copies forwarded to Health Secretary Wes Streeting.
Growing Public Opposition
Public sentiment against the trial has surged, with more than 137,000 individuals signing an e-petition opposing the study within just 72 hours. The drugs involved, which temporarily halt the development of secondary sex characteristics like breasts and menstrual cycles, were prohibited for use in gender medicine for individuals under 18 last year.
Support and Criticism from Key Figures
Baroness Hilary Cass, who led the independent 2024 review into NHS gender care, expressed support for the trial in a recent BBC interview. She argued that the research would establish a crucial evidence base and prevent unqualified practitioners from inappropriately prescribing these medications.
Conversely, prominent campaigners like Keira Bell, who previously challenged the Tavistock gender clinic in court after receiving puberty blockers and cross-sex hormones as a teenager, have welcomed Northern Ireland's suspension. Bell urged the UK government to follow suit, while psychotherapist James Esses called on Streeting to "pull the plug on this safeguarding monstrosity" to protect children.
The situation places Wes Streeting at the centre of a heated debate, balancing calls for rigorous scientific inquiry against concerns over child welfare and legal accountability. The outcome of the judicial review and subsequent government decisions will significantly influence the future of puberty blocker research in the UK.
